Did everyone see the new interview with Punit Dhillon??
Yes it's excellent thank you.
Here's the best parts for me-----------
[CF] I love the obvious adaptability of your OMS electroporation platform to potentially use any of a number of cancer treatment agents. Are there any plans on trying different chemotherapy or immunotherapy agents in the short to mid term?
[CEO] Yes, the company is continuing to evaluate several different agents, both chemotherapeutic and immunotherapeutic, in combination with our OMS electroporation device.
[CF] The trial data seems impressive so far. Can you put a "real world" perspective on the treatment in terms of its effect on an individual patient or patients?
[CEO] Certainly. In a recent article in the San Francisco Chronicle, David Amoroso, a patient undergoing a clinical trial at UCSF using ImmunoPulse for metastatic melanoma, had only a 24% chance of living to see the next decade. He started the study in March 2012, and our OMS treatment "seemingly zapped all but two of the six cancerous lumps that are evident." Mr. Amoroso commented "the fact that four tumors are gone," he said, "to me, seems successful." Mr. Amoroso elaborated comically on the only real side effects of the treatment "you're getting 1,300 volts, and all of a sudden it just hits you and you're in shock for about two seconds and there's no residual pain following it. It really feels like somebody whacked you with a two-by-four on the side of your head without pain."
[CF] What would you like to convey to potential shareholders from a financial and investment standpoint?
[CEO] I believe OncoSec is extremely undervalued considering our data and efficacy results. Our phase I data are best in class for any metastatic melanoma program in history. We have met every milestone that we have set out to reach from the birth of the company, have been extremely aggressive in our timelines and have exceeded our enrollment expectations for our programs. We have exciting milestones coming up - all to be complete by the end of 2012. These include but certainly aren't limited to revealing subset data from our melanoma and Merkel cell program and potentially providing updates on deals pertaining to our NeoPulse program.
[CF] Share price isn't there yet, but are there plans on uplisting to the big boards?
[CEO] Yes, the plan to uplist is in our future.
[CF] What sets OncoSec and its platform apart from the rest of the novel cancer therapies currently in development?
[CEO] OncoSec is uniquely positioning itself in the cancer immunotherapy space. For many years, scientists and clinicians have known that many cancers are caused by a dysfunction of the immune system, and as a result they have identified numerous immunological targets with potentially powerful benefits. Unfortunately, until now, the significance of these discoveries in terms of translation into success in the clinic has been disappointing largely in part due to the inability to properly deliver enough of these new agents to elicit a response while maintaining an acceptable level of safety for the patient.
Recently, new methods of delivery have been established such as viral vectors, cationic liposomes or autologous cell delivery, which carry DNA, or molecular instructions, directly to the cell to produce an immunogenic agent. This has been a revolution in cancer drug delivery because this route of administration not only targets the tumor directly, it also reduces the amount of agent required to elicit a therapeutic effect - therefore theoretically leading to potential improved responses and patient safety. Clinical trials using these routes of administration have demonstrated some success, but they have also come with some pitfalls. Early trials using adenoviral vectors resulted in significant safety issues, which have unfortunately delayed the development of this approach. Fortunately, it appears that these safety issues have been resolved and a number of companies have continued to develop immunotherapies using this viral vector approaches, however, it still remains unclear as to the long-term effects for the patient when delivering a biologic agent such as a virus. Cationic liposomes have demonstrated safety and some efficacy as well, however, the transfection efficiency (i.e. the ability to deliver the DNA to the cell with minimal effort and energy) is in question. As a result, clinical trials using this delivery method often require a number of treatments which can extend as long as 6-8 weeks. Lastly, the autologous cell delivery approach has recently received significant attention in cancer immunotherapy because it is the mode of delivery of choice of PROVENGE, the first cancer immunotherapy ever approved in the US. However, the attention received has been quite negative, particularly because it appears that this method, though effect, has proven to be prohibitively expensive for many patients and healthcare providers to consider as a primary or even secondary treatment option.
On the other hand, OncoSec has an established delivery method, electroporation, which provides the same benefits, while reducing the mitigating concerns related to other intralesional therapies. The OMS device uses electric fields to efficiently deliver DNA into cells. These electric fields are inert and dissipate once the electroporation is stopped, thus there is no concern about residual long-term effects. Moreover, the efficiency of delivery using electroporation is significantly better than other approaches. Where other treatments can last several weeks, results from our phase I study demonstrated that only 1-week of treatment could result in clinical benefit for late-stage cancer patients. Lastly, OncoSec's approach is simple and cost-effective. It is being developed as a potential out-patient clinic treatment, and the cost of goods for the company (i.e. device and DNA) is minimal. Taken all together, the ImmunoPulse treatment has demonstrated improved safety, efficacy and cost.